Abstract
Marine organisms are the excellent sources for biologically active compounds. Cnidarian venoms are potentially valuable materials used for biomedical research and drug development. The present work was carried out to analyse haemolytic, analgesic and CNS depressant activity of sea anemone Heteractis aurora. In haemolytic assay, among the five different RBC blood cells, the chicken blood exhibited maximum hemolytic activity of 64 Hemolytic Unit (HU). The maximum Analgesic Ratio (AR) of 5 recorded at 15 and 30 min interval and minimum was recorded after 45, 60 and 120 min time intervals. In jumping response activity, the maximum of 5 AR recorded at 15, 30 & 45 min and minimum was recorded at 90 & 120 min time intervals. The maximum decrease of depressant activity of 45.07% was determined in CNS depressant activity. Anti-inflammatory activity showed significant inhibition by crude extract of Heteractis aurora.
Keywords: Analgesic activity, CNS depressant activity, Heteractis aurora, Haemolytic activity, Sea anemone.
Central Nervous System Agents in Medicinal Chemistry
Title:Analgesic and CNS Depressant Activities of Sea Anemone Heteractis aurora Nematocyst Toxin
Volume: 16 Issue: 3
Author(s): Sengapillai Thangaraj, Subramanian Bragadeeswaran, Natarajah Srikumaran and Anbukkarasu Suguna
Affiliation:
Keywords: Analgesic activity, CNS depressant activity, Heteractis aurora, Haemolytic activity, Sea anemone.
Abstract: Marine organisms are the excellent sources for biologically active compounds. Cnidarian venoms are potentially valuable materials used for biomedical research and drug development. The present work was carried out to analyse haemolytic, analgesic and CNS depressant activity of sea anemone Heteractis aurora. In haemolytic assay, among the five different RBC blood cells, the chicken blood exhibited maximum hemolytic activity of 64 Hemolytic Unit (HU). The maximum Analgesic Ratio (AR) of 5 recorded at 15 and 30 min interval and minimum was recorded after 45, 60 and 120 min time intervals. In jumping response activity, the maximum of 5 AR recorded at 15, 30 & 45 min and minimum was recorded at 90 & 120 min time intervals. The maximum decrease of depressant activity of 45.07% was determined in CNS depressant activity. Anti-inflammatory activity showed significant inhibition by crude extract of Heteractis aurora.
Export Options
About this article
Cite this article as:
Thangaraj Sengapillai, Bragadeeswaran Subramanian, Srikumaran Natarajah and Suguna Anbukkarasu, Analgesic and CNS Depressant Activities of Sea Anemone Heteractis aurora Nematocyst Toxin, Central Nervous System Agents in Medicinal Chemistry 2016; 16 (3) . https://dx.doi.org/10.2174/1871524916666160129101049
DOI https://dx.doi.org/10.2174/1871524916666160129101049 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Drugs Promoting Wakefulness and Performance Executive Editor: J.G. Ramaekers]
Current Pharmaceutical Design Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance
Current Neuropharmacology Exploring the Role of Nerve Growth Factor in Multiple Sclerosis: Implications in Myelin Repair
CNS & Neurological Disorders - Drug Targets Family Psychoeducation in Clinical High Risk and First-Episode Psychosis
Adolescent Psychiatry The Effect of Acori Graminei Rhizoma and Extract Fractions on Spatial Memory and Hippocampal Neurogenesis in Amyloid Beta 1-42 Injected Mice
CNS & Neurological Disorders - Drug Targets Mechanisms of Neutrophil-mediated Disease: Innovative Therapeutic Interventions
Current Pharmaceutical Design Health Consequences of Catabolic Synthesis of Hippuric Acid in Humans
Current Clinical Pharmacology Behavioural Sensitisation During Dopamine Replacement Therapy in Parkinsons Disease is Reminiscent of the Addicted Brain
Current Topics in Medicinal Chemistry High Resolution M-mode Evaluation of Jugular Vein Valves in Patients with Neurological and Neurosensory Disorders
Current Neurovascular Research Metabolism of the Endocannabinoids Anandamide and 2-Arachidonoyl Glycerol, A Review, with Emphasis on the Pharmacology of Fatty Acid Amide Hydrolase, A Possible Target for the Treatment of Neurodegenerative Diseases and Pain
Current Medicinal Chemistry - Central Nervous System Agents The Key Role of Medullary 5-HT3 Receptors in the Serotonin-Mediated Neural Control of Cardiovascular Function
Current Neuropharmacology INNO-206 (DOXO-EMCH), an Albumin-Binding Prodrug of Doxorubicin Under Development for Phase II Studies
Current Bioactive Compounds S100b Induces Expression of Myoglobin in APβ Treated Neuronal Cells In Vitro: A Possible Neuroprotective Mechanism
Current Aging Science Targeting Lung Inflammation: Novel Therapies for the Treatment of COPD
Current Respiratory Medicine Reviews Purinergic Signaling and Hippocampal Long-Term Potentiation
Current Neuropharmacology Aquaporins and Neurodegenerative Diseases
Current Neuropharmacology Alterations of Brain Membranes in Schizophrenia: Impact of Phospholipase A2
Current Topics in Medicinal Chemistry Clinical Herbal Interactions with Conventional Drugs: From Molecules to Maladies
Current Medicinal Chemistry Preface (New Research Frontiers and Advances in Drug Addiction)
Current Neuropharmacology Editorial (Thematic Issue: Phytochemicals for Human Diseases: An Update)
Current Pharmaceutical Biotechnology